A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma.

Autoria(s): Eatock, Martin
Data(s)

01/03/2008
Identificador

http://pure.qub.ac.uk/portal/en/publications/a-phase-ii-openlabel-study-of-dhapaclitaxel-taxoprexin-by-2h-intravenous-infusion-in-previously-untreated-patients-with-locally-advanced-or-metastatic-gastric-or-oesophageal-adenocarcinoma(b0ace970-f7c5-4af7-a428-283502299e84).html

http://dx.doi.org/10.1007/s00280-007-0486-8

http://www.scopus.com/inward/record.url?scp=37249036585&partnerID=8YFLogxK
Idioma(s)

eng
Direitos

info:eu-repo/semantics/restrictedAccess
Fonte

Eatock , M 2008 , ' A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. ' Cancer Chemotherapy and Pharmacology , vol 61(3) , no. 3 , pp. 435-441 . DOI: 10.1007/s00280-007-0486-8
Palavras-Chave #/dk/atira/pure/subjectarea/asjc/1300/1306 #Cancer Research #/dk/atira/pure/subjectarea/asjc/3000/3004 #Pharmacology #/dk/atira/pure/subjectarea/asjc/2700/2730 #Oncology
Tipo

article
Acesso ao item digital